Your shopping cart is currently empty

BC-1901S functions as a proteasome-independent activator and stabilizer of NRF2. By binding to DCAF1 (E3 ligase subunit), it disrupts the NRF2/DCAF1 interaction and activates NRF2 through the inhibition of NRF2 ubiquitination, independent of KEAP1. BC-1901S has demonstrated anti-inflammatory effects in a murine model of LPS-induced acute lung injury.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
| Description | BC-1901S functions as a proteasome-independent activator and stabilizer of NRF2. By binding to DCAF1 (E3 ligase subunit), it disrupts the NRF2/DCAF1 interaction and activates NRF2 through the inhibition of NRF2 ubiquitination, independent of KEAP1. BC-1901S has demonstrated anti-inflammatory effects in a murine model of LPS-induced acute lung injury. |
| Molecular Weight | 424.90 |
| Formula | C23H22ClFN4O |
| Cas No. | 1358617-36-3 |
| Smiles | O=C(NC1=CC=C(F)C(Cl)=C1)C2CCN(C3=NC(=NC=C3)C=4C=CC=C(C4)C)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.